Finding novel distinctions between the sAPPα-mediated anabolic biochemical pathways in Autism Spectrum Disorder and Fragile X Syndrome plasma and brain tissue

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Ray, Balmiki ^a   Sokol, Deborah K ^a   Maloney, Bryan ^a   Lahiri, Debomoy K ^a,b  

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; AMYLOID PRECURSOR PROTEIN; ASPARTIC PROTEINASE; BACE1 PROTEIN, HUMAN; BIOLOGICAL MARKER; SECRETASE;

ADOLESCENT; AGE; AMYGDALA; ANTIBODY SPECIFICITY; AUTISM; CHILD; COMPARATIVE STUDY; FRAGILE X SYNDROME; HUMAN; METABOLISM; PATHOLOGY; PLASMA; PRESCHOOL CHILD; PROTEIN PROCESSING; YOUNG ADULT;

ADOLESCENT; AGE FACTORS; AMYGDALA; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; AMYLOID PRECURSOR PROTEIN SECRETASES; ASPARTIC ACID ENDOPEPTIDASES; AUTISM SPECTRUM DISORDER; BIOMARKERS; CHILD; CHILD, PRESCHOOL; FRAGILE X SYNDROME; HUMANS; ORGAN SPECIFICITY; PLASMA; PROTEIN PROCESSING, POST-TRANSLATIONAL; YOUNG ADULT;

EID: 84971260493     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26052     Document Type: Article

References (119)

1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th edn, (American Psychiatric Association, 2013).
2. Peprah, E. Fragile X syndrome: the FMR1 CGG repeat distribution among world populations. Ann. Hum. Genet. 76, 178-191, doi: 10.1111/j.1469-1809.2011.00694.x (2012).
3. Coffee, B. et al. Mosaic FMR1 deletion causes fragile X syndrome and can lead to molecular misdiagnosis: a case report and review of the literature. Am. J. Med. Genet. A 146A, 1358-1367, doi: 10.1002/ajmg.a.32261 (2008).
4. Ebert, D. H. & Greenberg, M. E. Activity-dependent neuronal signalling and autism spectrum disorder. Nature 493, 327-337, doi: 10.1038/nature11860 (2013).
5. Wang, L. W., Berry-Kravis, E. & Hagerman, R. J. Fragile X: leading the way for targeted treatments in autism. Neurotherapeutics 7, 264-274, doi: 10.1016/j.nurt.2010.05.005 (2010).
6. Hutsler, J. J. & Zhang, H. Increased dendritic spine densities on cortical projection neurons in autism spectrum disorders. Brain Res. 1309, 83-94, doi: 10.1016/j.brainres.2009.09.120 (2010).
7. Irwin, S. A., Galvez, R. & Greenough, W. T. Dendritic spine structural anomalies in fragile-X mental retardation syndrome. Cereb. Cortex 10, 1038-1044 (2000).
8. Haas, B. W. et al. Early white-matter abnormalities of the ventral frontostriatal pathway in fragile X syndrome. Dev. Med. Child Neurol. 51, 593-599, doi: 10.1111/j.1469-8749.2009.03295.x (2009).
9. Sundaram, S. K. et al. Diffusion tensor imaging of frontal lobe in autism spectrum disorder. Cereb. Cortex 18, 2659-2665, doi: 10.1093/cercor/bhn031 (2008).
10. Mullan, M. & Crawford, F. Genetic and molecular advances in Alzheimer's disease. Trends Neurosci. 16, 398-403 (1993).
11. Jolly-Tornetta, C., Gao, Z. Y., Lee, V. M. & Wolf, B. A. Regulation of amyloid precursor protein secretion by glutamate receptors in human Ntera 2 neurons. J. Biol. Chem. 273, 14015-14021 (1998).
12. Mattson, M. P. Secreted forms of beta-amyloid precursor protein modulate dendrite outgrowth and calcium responses to glutamate in cultured embryonic hippocampal neurons. J. Neurobiol. 25, 439-450, doi: 10.1002/neu.480250409 (1994).
13. Lahiri, D. K., Farlow, M. R., Greig, N. H. & Sambamurti, K. Current drug targets for Alzheimer's disease treatment. Drug. Dev. Res. 56, 267-281 (2002).
14. Alzheimer's Association. 2014 Alzheimer's disease facts and figures. Alzheimers Dement. 10, e47-92 (2014).
15. Ray, B., Long, J. M., Sokol, D. K. & Lahiri, D. K. Increased secreted amyloid precursor protein-alpha (sAPPalpha) in severe autism: proposal of a specific, anabolic pathway and putative biomarker. Plos One 6, e20405, doi: 10.1371/journal.pone.0020405 (2011).
16. Lahiri, D. K. et al. Autism as early neurodevelopmental disorder: evidence for an sAPPalpha-mediated anabolic pathway. Front. Cell. Neurosci. 7, 94, doi: 10.3389/fncel.2013.00094 (2013).
17. Sokol, D. K. et al. High levels of Alzheimer beta-amyloid precursor protein (APP) in children with severely autistic behavior and aggression. J. Child Neurol. 21, 444-449 (2006).
18. Sokol, D. K., Ray, B., Ekanayake, V. & Lahiri, D. K. Increased non-amyloidgenic sAPPa in brain tissue of children with severe autism. Paper presented at Miami 2014 Winter Symposium: The Molecular Basis of Brain Disorders, Miami, FL. Miami, FL: Elsevier, (2014, Jan 26).
19. Bailey, A. R. et al. Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. Int. J. Clin. Exp. Med. 1, 338-344 (2008).
20. Bailey, A. R. et al. GFAP expression and social deficits in transgenic mice overexpressing human sAPPalpha. Glia 61, 1556-1569, doi: 10.1002/glia.22544 (2013).
21. Erickson, C., Ray, B., McDougle, C. J., Sokol, D. K. & Lahiri, D. K. Impact of Acamprosate on Plasma Amyloid Precursor Protein in Youth: A Pilot Analysis in Fragile X Syndrome-Associated and Idiopathic Autism Spectrum Disorder Suggests a Pharmacodynamic Protein Marker. J. Psychiatr. Res. 59, 220-228, doi: 10.1016/j.jpsychires.2014.07.011 (2014).
22. Langen, M., Durston, S., Staal, W. G., Palmen, S. J. M. C. & Engeland, H. v. Caudate nucleus is enlarged in high-functioning medication-naive subjects with autism. Biol. Psychiatry 62, 262-266, doi: 10.1016/j.biopsych.2006.09.040 (2007).
23. Gothelf, D. et al. Neuroanatomy of fragile X syndrome is associated with aberrant behavior and the fragile X mental retardation protein (FMRP). Ann. Neurol. 63, 40-51, doi: 10.1002/ana.21243 (2008).
24. Mosconi, M. W. et al. Longitudinal study of amygdala volume and joint attention in 2-to 4-year-old children with autism. Arch. Gen. Psychiatry 66, 509-516, doi: 10.1001/archgenpsychiatry.2009.19 (2009).
25. Hazlett, H. C. et al. Teasing apart the heterogeneity of autism: Same behavior, different brains in toddlers with fragile X syndrome and autism. J. Neurodev. Disord. 1, 81-90, doi: 10.1007/s11689-009-9009-8 (2009).
26. Poulin, S. P. et al. Amygdala atrophy is prominent in early Alzheimer's disease and relates to symptom severity. Psychiatry Res. 194, 7-13, doi: 10.1016/j.pscychresns.2011.06.014 (2011).
27. Schumann, C. M., Barnes, C. C., Lord, C. & Courchesne, E. Amygdala enlargement in toddlers with autism related to severity of social and communication impairments. Biol. Psychiatry 66, 942-949, doi: 10.1016/j.biopsych.2009.07.007 (2009).
28. Westmark, C. J. & Malter, J. S. FMRP mediates mGluR5-dependent translation of amyloid precursor protein. Plos Biol. 5, e52, doi: 10.1371/journal.pbio.0050052 (2007).
29. Westmark, C. J., Westmark, P. R., Beard, A. M., Hildebrandt, S. M. & Malter, J. S. Seizure Susceptibility and Mortality in Mice that Over-Express Amyloid Precursor Protein. Int. J. Clin. Exp. Pathol. 1, 157-168 (2008).
30. Westmark, C. J. et al. Reversal of fragile X phenotypes by manipulation of AbetaPP/Abeta levels in Fmr1KO mice. Plos One 6, e26549, doi: 10.1371/journal.pone.0026549 (2011).
31. Huber, K. M., Gallagher, S. M., Warren, S. T. & Bear, M. F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. USA 99, 7746-7750, doi: 10.1073/pnas.122205699 (2002).
32. Huber, K. M., Roder, J. C. & Bear, M. F. Chemical induction of mGluR5-and protein synthesis - dependent long-term depression in hippocampal area CA1. J. Neurophysiol. 86, 321-325 (2001).
33. Sokol, D. K., Maloney, B., Long, J. M., Ray, B. & Lahiri, D. K. Autism, Alzheimer disease, and fragile X: APP, FMRP, and mGluR5 are molecular links. Neurology 76, 1344-1352, doi: 10.1212/WNL.0b013e3182166dc7 (2011).
34. Bear, M. F., Huber, K. M. & Warren, S. T. The mGluR theory of fragile X mental retardation. Trends Neurosci. 27, 370-377, doi: 10.1016/j.tins.2004.04.009 (2004).
35. Burnham, K. P. & R, A. D. Model Selection and Multimodel Inference: A Practical Information-Theoretic Approach. 2nd edn, (Springer-Verlag, 2002).
36. Vogel-Ciernia, A. & Wood, M. A. Neuron-specific chromatin remodeling: a missing link in epigenetic mechanisms underlying synaptic plasticity, memory, and intellectual disability disorders. Neuropharmacology 80, 18-27, doi: 10.1016/j. neuropharm.2013.10.002 (2014).
37. Luscher, C. & Malenka, R. C. NMDA receptor-dependent long-term potentiation and long-term depression (LTP/LTD). Cold Spring Harb. Perspect. Biol. 4, a005710, doi: 10.1101/cshperspect.a005710 (2012).
38. Monaco, A. P. & Bailey, A. J. & International Molecular Genetic Study of Autism Consortium (IMGSAC). A genomewide screen for autism: strong evidence for linkage to chromosomes 2q, 7q, and 16p. Am. J. Hum. Genet. 69, 570-581, doi: 10.1086/323264 (2001).
39. Selemon, L. D. A role for synaptic plasticity in the adolescent development of executive function. Transl. Psychiatry 3, e238, doi: 10.1038/tp.2013.7 (2013).
40. Buoso, E. et al. Modulation of Rack-1/PKCbetaII signalling by soluble AbetaPPalpha in SH-SY5Y cells. Curr. Alzheimer Res. 10, 697-705, doi: 10.2174/15672050113109990145 (2013).
41. Bailey, A. R. et al. Aberrant T-lymphocyte development and function in mice overexpressing human soluble amyloid precursor protein-alpha: implications for autism. FASEB J. 26, 1040-1051, doi: 10.1096/fj.11-195438 (2012).
42. Kelleher, R. J., 3rd & Bear, M. F. The autistic neuron: troubled translation? Cell 135, 401-406, doi: 10.1016/j.cell.2008.10.017 (2008).
43. Galvez, R. & Greenough, W. T. Sequence of abnormal dendritic spine development in primary somatosensory cortex of a mouse model of the fragile X mental retardation syndrome. Am. J. Med. Genet. A 135, 155-160, doi: 10.1002/ajmg.a.30709 (2005).
44. Rudelli, R. D. et al. Adult fragile X syndrome. Clinico-neuropathologic findings. Acta Neuropathol. 67, 289-295, doi: 10.1007/BF00687814 (1985).
45. Zheng, H. & Koo, E. H. The amyloid precursor protein: beyond amyloid. Mol. Neurodegener. 1, 5, doi: 10.1186/1750-1326-1-5 (2006).
46. O'Roak, B. J. et al. Sporadic autism exomes reveal a highly interconnected protein network of de novo mutations. Nature 485, 246-250, doi: 10.1038/nature10989 (2012).
47. Hazlett, H. C. et al. Early brain overgrowth in autism associated with an increase in cortical surface area before age 2 years. Arch. Gen. Psychiatry 68, 467-476, doi: 10.1001/archgenpsychiatry.2011.39 (2011).
48. Tawk, M. et al. Wnt/beta-catenin signaling is an essential and direct driver of myelin gene expression and myelinogenesis. J. Neurosci. 31, 3729-3742, doi: 10.1523/JNEUROSCI.4270-10.2011 (2011).
49. State, M. W. & Levitt, P. The conundrums of understanding genetic risks for autism spectrum disorders. Nat. Neurosci. 14, 1499-1506, doi: 10.1038/nn.2924 (2011).
50. Bagni, C. & Greenough, W. T. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. Nat. Rev. Neurosci. 6, 376-387, doi: 10.1038/nrn1667 (2005).
51. D'Hulst, C. & Kooy, R. F. Fragile X syndrome: from molecular genetics to therapy. J. Med. Genet. 46, 577-584, doi: 10.1136/jmg.2008.064667 (2009).
52. Tsai, N. P. et al. Multiple autism-linked genes mediate synapse elimination via proteasomal degradation of a synaptic scaffold PSD-95. Cell 151, 1581-1594, doi: 10.1016/j.cell.2012.11.040 (2012).
53. Tang, G. et al. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron 83, 1131-1143, doi: 10.1016/j.neuron.2014.07.040 (2014).
54. Fatemi, S. H. & Folsom, T. D. Dysregulation of fragile x mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study. Mol. Autism 2, 6, doi: 10.1186/2040-2392-2-6 (2011).
55. Cvetkovska, V., Hibbert, A. D., Emran, F. & Chen, B. E. Overexpression of Down syndrome cell adhesion molecule impairs precise synaptic targeting. Nat. Neurosci. 16, 677-682, doi: 10.1038/nn.3396 (2013).
56. Luca, R. et al. The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. EMBO Mol. Med. 5, 1523-1536, doi: 10.1002/emmm.201302847 (2013).
57. Schultz-Pedersen, S., Hasle, H., Olsen, J. H. & Friedrich, U. Evidence of decreased risk of cancer in individuals with fragile X. Am. J. Med. Genet. 103, 226-230, doi: 10.1002/ajmg.1533 (2001).
58. Muller, U. C. & Zheng, H. Physiological functions of APP family proteins. Cold Spring Harb. Perspect. Med. 2, a006288, doi: 10.1101/cshperspect.a006288 (2012).
59. Wang, Z. et al. Presynaptic and postsynaptic interaction of the amyloid precursor protein promotes peripheral and central synaptogenesis. J. Neurosci. 29, 10788-10801, doi: 10.1523/JNEUROSCI.2132-09.2009 (2009).
60. Young-Pearse, T. L., Chen, A. C., Chang, R., Marquez, C. & Selkoe, D. J. Secreted APP regulates the function of full-length APP in neurite outgrowth through interaction with integrin beta1. Neural Dev. 3, 15, doi: 10.1186/1749-8104-3-15 (2008).
61. Chen, Y. & Bodles, A. M. Amyloid precursor protein modulates beta-catenin degradation. J. Neuroinflammation 4, 29, doi: 10.1186/1742-2094-4-29 (2007).
62. Venezia, V. et al. Amyloid precursor protein modulates ERK-1 and-2 signaling. Ann. N. Y. Acad. Sci. 1090, 455-465, doi: 10.1196/annals.1378.048 (2006).
63. Bhaskar, K. et al. The PI3K-Akt-mTOR pathway regulates Abeta oligomer induced neuronal cell cycle events. Mol. Neurodegener. 4, 14, doi: 10.1186/1750-1326-4-14 (2009).
64. Goebel-Goody, S. M. et al. Therapeutic implications for striatal-enriched protein tyrosine phosphatase (STEP) in neuropsychiatric disorders. Pharmacol. Rev. 64, 65-87, doi: 10.1124/pr.110.003053 (2012).
65. Goebel-Goody, S. M. & Lombroso, P. J. Taking STEPs forward to understand fragile X syndrome. Results Probl. Cell Differ. 54, 223-241, doi: 10.1007/978-3-642-21649-7-12 (2012).
66. Chuang, S. C. et al. Prolonged epileptiform discharges induced by altered group I metabotropic glutamate receptor-mediated synaptic responses in hippocampal slices of a fragile X mouse model. J. Neurosci. 25, 8048-8055, doi: 10.1523/JNEUROSCI.1777-05.2005 (2005).
67. Lahiri, D. K. & Maloney, B. Beyond the signaling effect role of amyloid-beta42 on the processing of APP, and its clinical implications. Exp. Neurol. 225, 51-54, doi: 10.1016/j.expneurol.2010.04.018 (2010).
68. Vitolo, O. V. et al. Amyloid beta-peptide inhibition of the PKA/CREB pathway and long-term potentiation: reversibility by drugs that enhance cAMP signaling. Proc. Natl. Acad. Sci. USA 99, 13217-13221, doi: 10.1073/pnas.172504199 (2002).
69. Taylor, C. J. et al. Endogenous secreted amyloid precursor protein-alpha regulates hippocampal NMDA receptor function, longterm potentiation and spatial memory. Neurobiol. Dis. 31, 250-260, doi: 10.1016/j.nbd.2008.04.011 (2008).
70. Garber, K., Smith, K. T., Reines, D. & Warren, S. T. Transcription, translation and fragile X syndrome. Curr. Opin. Genet. Dev. 16, 270-275, doi: 10.1016/j.gde.2006.04.010 (2006).
71. Izumi, R. et al. Positive and negative regulatory elements for the expression of the Alzheimer's disease amyloid precursor-encoding gene in mouse. Gene 112, 189-195, doi: 10.1016/0378-1119(92)90375-Y (1992).
72. Lukiw, W. J. et al. Protein-DNA interactions in the promoter region of the amyloid precursor protein (APP) gene in human neocortex. Brain Res. Mol. Brain Res. 22, 121-131, doi: 10.1016/0169-328X(94)90039-6 (1994).
73. Querfurth, H. W., Jiang, J., Xia, W. & Selkoe, D. J. Enhancer function and novel DNA binding protein activity in the near upstream betaAPP gene promoter. Gene 232, 125-141, doi: 10.1016/S0378-1119(99)00091-8 (1999).
74. Citron, B. A., Dennis, J. S., Zeitlin, R. S. & Echeverria, V. Transcription factor Sp1 dysregulation in Alzheimer's disease. J. Neurosci. Res. 86, 2499-2504, doi: 10.1002/jnr.21695 (2008).
75. Thanseem, I. et al. Elevated transcription factor specificity protein 1 in autistic brains alters the expression of autism candidate genes. Biol. Psychiatry 71, 410-418, doi: 10.1016/j.biopsych.2011.09.020 (2012).
76. Fatemi, S. H. et al. Reelin signaling is impaired in autism. Biol. Psychiatry 57, 777-787, doi: 10.1016/j.biopsych.2004.12.018 (2005).
77. Seripa, D. et al. The RELN locus in Alzheimer's disease. J. Alzheimers Dis. 14, 335-344 (2008).
78. Ryan, M. M. et al. Time-dependent changes in gene expression induced by secreted amyloid precursor protein-alpha in the rat hippocampus. BMC Genomics 14, 376, doi: 10.1186/1471-2164-14-376 (2013).
79. Lin, Y. et al. Activity-dependent regulation of inhibitory synapse development by Npas4. Nature 455, 1198-1204, doi: 10.1038/nature07319 (2008).
80. Ge, Y. W. & Lahiri, D. K. Regulation of promoter activity of the APP gene by cytokines and growth factors: implications in Alzheimer's disease. Ann. N. Y. Acad. Sci. 973, 463-467, doi: 10.1111/j.1749-6632.2002.tb04684.x (2002).
81. Ebert, D. H. et al. Activity-dependent phosphorylation of MeCP2 threonine 308 regulates interaction with NCoR. Nature 499, 341-345, doi: 10.1038/nature12348 (2013).
82. Tolwani, R. J. et al. BDNF overexpression produces a long-term increase in myelin formation in the peripheral nervous system. J. Neurosci. Res. 77, 662-669, doi: 10.1002/jnr.20181 (2004).
83. Nelson, K. B. et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann. Neurol. 49, 597-606, doi: 10.1002/ana.1024 (2001).
84. Croen, L. A. et al. Brain-derived neurotrophic factor and autism: maternal and infant peripheral blood levels in the Early Markers for Autism (EMA) Study. Autism Res. 1, 130-137, doi: 10.1002/aur.14 (2008).
85. Barger, S. W. & Harmon, A. D. Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388, 878-881, doi: 10.1038/42257 (1997).
86. Clifford, S. et al. Autism spectrum phenotype in males and females with fragile X full mutation and premutation. J. Autism Dev. Disord. 37, 738-747, doi: 10.1007/s10803-006-0205-z (2007).
87. Harris, S. W. et al. Autism profiles of males with fragile X syndrome. Am. J. Ment. Retard. 113, 427-438, doi: 10.1352/2008.113:427-438 (2008).
88. Hall, S. S., Lightbody, A. A., Hirt, M., Rezvani, A. & Reiss, A. L. Autism in fragile X syndrome: a category mistake? J. Am. Acad. Child Adolesc. Psychiatry 49, 921-933, doi: 10.1016/j.jaac.2010.07.001 (2010).
89. Dissanayake, C., Bui, Q., Bulhak-Paterson, D., Huggins, R. & Loesch, D. Z. Behavioural and cognitive phenotypes in idiopathic autism versus autism associated with fragile X syndrome. J. Child Psychol. Psychiatry 50, 290-299, doi: 10.1111/j.1469-7610.2008.01988.x (2009).
90. McDuffie, A. et al. Autism spectrum disorder in children and adolescents with fragile X syndrome: within-syndrome differences and age-related changes. Am. J. Intellect. Dev. Disabil. 115, 307-326, doi: 10.1352/1944-7558-115.4.307 (2010).
91. Loth, E. et al. Identification and validation of biomarkers for autism spectrum disorders. Nat. Rev. Drug. Discov. 15, 70-73, doi: 10.1038/nrd.2015.7 (2015).
92. Zaman, S. et al. A Search for Blood Biomarkers for Autism: Peptoids. Sci. Rep. 6, 19164, doi: 10.1038/srep19164 (2016).
93. Ghosh, A., Michalon, A., Lindemann, L., Fontoura, P. & Santarelli, L. Drug discovery for autism spectrum disorder: challenges and opportunities. Nat. Rev. Drug. Discov. 12, 777-790, doi: 10.1038/nrd4102 (2013).
94. Palazuelos, J. et al. TACE/ADAM17 is essential for oligodendrocyte development and CNS myelination. J. Neurosci. 34, 11884-11896, doi: 10.1523/JNEUROSCI.1220-14.2014 (2014).
95. Hartl, D. et al. Soluble alpha-APP (sAPPalpha) regulates CDK5 expression and activity in neurons. Plos One 8, e65920, doi: 10.1371/journal.pone.0065920 (2013).
96. Zhang, Y. W. et al. APP regulates NGF receptor trafficking and NGF-mediated neuronal differentiation and survival. Plos One 8, e80571, doi: 10.1371/journal.pone.0080571 (2013).
97. Buggia-Prevot, V. & Thinakaran, G. Sorting the role of SORLA in Alzheimer's disease. Sci. Transl. Med. 6, 223fs228, doi: 10.1126/scitranslmed.3008562 (2014).
98. Wang, L. et al. No association of polymorphisms in the CDK5, NDEL1, and LIS1 with autism in Chinese Han population. Psychiatry Res. 190, 369-371, doi: 10.1016/j.psychres.2011.08.004 (2011).
99. Hasebe, N. et al. Soluble beta-amyloid Precursor Protein Alpha binds to p75 neurotrophin receptor to promote neurite outgrowth. Plos One 8, e82321, doi: 10.1371/journal.pone.0082321 (2013).
100. Almeida, L. E., Roby, C. D. & Krueger, B. K. Increased BDNF expression in fetal brain in the valproic acid model of autism. Mol. Cell. Neurosci. 59, 57-62, doi: 10.1016/j.mcn.2014.01.007 (2014).
101. Cohen, R. I., Marmur, R., Norton, W. T., Mehler, M. F. & Kessler, J. A. Nerve growth factor and neurotrophin-3 differentially regulate the proliferation and survival of developing rat brain oligodendrocytes. J. Neurosci. 16, 6433-6442 (1996).
102. Sokol, D. K., Ho, C., Maloney, B. & Lahiri, D. K. Enlarged Brain Volume and elevated secreted amyloid precursor protein-alpha in autism are consistent with sAPP mediated anabolic pathway and macrocephaly. Arch. Clin. Neuropsychol. 30, 548-549, doi: 10.1093/arclin/acv047.166 (2015).
103. Li, H. et al. Soluble amyloid precursor protein (APP) regulates transthyretin and Klotho gene expression without rescuing the essential function of APP. Proc. Natl. Acad. Sci. USA 107, 17362-17367, doi: 10.1073/pnas.1012568107 (2010).
104. Lahiri, D. K. et al. The experimental Alzheimer's disease drug posiphen [(+ )-phenserine] lowers amyloid-beta peptide levels in cell culture and mice. J. Pharmacol. Exp. Ther. 320, 386-96, doi: 10.1124/jpet.106.112102 (2007).
105. Berry-Kravis, E. et al. Mavoglurant in fragile X syndrome: Results of two randomized, double-blind, placebo-controlled trials. Sci. Transl. Med. 8, 321ra325, doi: 10.1126/scitranslmed.aab4109 (2016).
106. Carrol, J. Roche abandons another Fragile X R&D program after PhII trials flunk out, http://www.fiercebiotech.com/r-d/rocheabandons-another-fragile-x-r-d-program-after-phii-trials-flunk-out, Date of Access: 11 April (2015).
107. Bandyopadhyay, S. et al. Novel 5' untranslated region directed blockers of iron-regulatory protein-1 dependent amyloid precursor protein translation: implications for down syndrome and Alzheimer's disease. Plos One 8, e65978, doi: 10.1371/journal. pone.0065978 (2013).
108. Ray, B., Banerjee, P. K., Greig, N. H. & Lahiri, D. K. Memantine treatment decreases levels of secreted Alzheimer's amyloid precursor protein (APP) and amyloid beta (A beta) peptide in the human neuroblastoma cells. Neurosci. Lett. 470, 1-5, doi: 10.1016/j.neulet.2009.11.016 (2010).
109. Alley, G. M. et al. Memantine lowers amyloid-beta peptide levels in neuronal cultures and in APP/PS1 transgenic mice. J. Neurosci. Res. 88, 143-154, doi: 10.1002/jnr.22172 (2010).
110. Tripathy, D. et al. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study. Diabetologia 56, 2153-2163, doi: 10.1007/s00125-013-2976-z (2013).
111. To, A. W., Ribe, E. M., Chuang, T. T., Schroeder, J. E. & Lovestone, S. The epsilon3 and epsilon4 alleles of human APOE differentially affect tau phosphorylation in hyperinsulinemic and pioglitazone treated mice. Plos One 6, e16991, doi: 10.1371/journal. pone.0016991 (2011).
112. Lee, G. & Leugers, C. J. Tau and tauopathies. Prog. Mol. Biol. Transl. Sci. 107, 263-293, doi: 10.1016/B978-0-12-385883-2.00004-7 (2012).
113. Nousen, E. K., Franco, J. G. & Sullivan, E. L. Unraveling the mechanisms responsible for the comorbidity between metabolic syndrome and mental health disorders. Neuroendocrinology 98, 254-266, doi: 10.1159/000355632 (2013).
114. US National Institutes of Health. Study of XL784 in Patients With Albuminuria Due to Diabetic Nephropathy, https://clinicaltrials. gov/ct2/show/NCT00312780 (2010) Date of Access: February 17, 2016.
115. Kim, M. L. et al. Effects of TNFalpha-converting enzyme inhibition on amyloid beta production and APP processing in vitro and in vivo. J. Neurosci. 28, 12052-12061, doi: 10.1523/JNEUROSCI.2913-08 (2008).
116. Long, J. M., Ray, B. & Lahiri, D. K. MicroRNA-339-5p down-regulates protein expression of beta-site amyloid precursor proteincleaving enzyme 1 (BACE1) in human primary brain cultures and is reduced in brain tissue specimens of Alzheimer disease subjects. J. Biol. Chem. 289, 5184-5198, doi: 10.1074/jbc.M113.518241 (2014).
117. Maxmen, A. Brains thaw at Harvard repository, http://blogs.nature.com/news/2012/06/brains-thaw-at-harvard-repository.html (2012) Date of Access: 14 March 2016.
118. Hedges, L. V. & Olkin, I. Statistical Methods for Meta-Analysis. (Academic Press, 1985).
119. Olejnik, S. & Algina, J. Generalized eta and omega squared statistics: measures of effect size for some common research designs. Psychol. Methods 8, 434-447, doi: 10.1037/1082-989X.8.4.434 (2003).